Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial von Armstrong, April W, Gooderham, Melinda, Lynde, Charles, Maari, Catherine, Forman, Seth, Green, Lawrence, Laquer, Vivian, Zhang, Xinyan, Franchimont, Nathalie, Gangolli, Esha A, Blau, Jessamyn, Zhao, Yiwei, Zhang, Wenwen, Srivastava, Bhaskar, Heap, Graham, Papp, Kim

Volltext

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial von Kim, Seung Tae, Lee, Sujin, Park, Minhwa, Park, Se Hoon, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Gangolli, Esha A., Shin, Hyeongchan, Kim, Kyoung-Mee, Hollingsworth, Simon J., Mortimer, Peter G.S., Lee, Jeeyun

Volltext

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants von Micel, Lindsey N, Tentler, John J, Tan, Aik-Choon, Selby, Heather M, Brunkow, Kelsey L, Robertson, Kelli M, Davis, S Lindsey, Klauck, Peter J, Pitts, Todd M, Gangolli, Esha, Fabrey, Robyn, O'Connell, Shawn M, Vincent, Patrick W, Eckhardt, S Gail

Volltext

1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response von Ciccone, David, Kuo, Fu-Shan, Boiko, Scott, Daigle, Scott, Carreiro, Samantha, Kaila, Neelu, Yau, Gene, Gangolli, Esha A, Levasseur, Denise, Srivastava, Bhaskar, Basile, Frank G, Loh, Christine

Volltext

751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor von Sommerhalder, David, Noel, Marcus, Boiko, Scott, Daigle, Scott, Zhang, Xinyan, Fraser, Patricia, Hoerres, Amanda, Rana, Nawaid, Gangolli, Esha A, Basile, Frank G, Srivastava, Bhaskar, Sharma, Sunil, Balaraman, Rama, Gutierrez, Martin

Volltext

Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients von Rao, Arpit, Ryan, Charles J., Morris, David, Assikis, Vasileios, Jha, Gautam, Ablaza, Adriel-John, Habeck, Jenn, Loehr, Andrea, Xiao, Jim, Gangolli, Esha A.

Volltext

Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study von Rao, Arpit, Morris, David, Assikis, Vasily J., Jha, Gautam Gopalji, Ryan, Charles J., Ablaza, Adriel-John, Habeck, Jenn, Loehr, Andrea, Xiao, Jim, Gangolli, Esha A.

Volltext

Phase 1 trial of the adenosine A 2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A 2A... von Buisseret, Laurence, Rottey, Sylvie, De Bono, Johann S., Migeotte, Ariane, Delafontaine, Brant, Manickavasagar, Thubeena, Martinoli, Chiara, Wald, Noémie, Rossetti, Maura, Gangolli, Esha A., Wiegert, Erol, McIntyre, Nicola, Lager, Joanne J., Machiels, Jean-Pascal H.

Volltext

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors von Goldman, Jonathan, Eckhardt, S Gail, Borad, Mitesh J, Curtis, Kelly K, Hidalgo, Manuel, Calvo, Emiliano, Ryan, David P, Wirth, Lori J, Parikh, Asit, Partyka, James, Faessel, Helene, Gangolli, Esha, Stewart, Sally, Rosen, Lee S, Bowles, Daniel W

Volltext

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors von Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana

Volltext

Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial... von Kannan, Karuppiah, Fabrey, Robyn, Cooper, Jodi, Huck, Jessica, Gangolli, Esha, Westin, Eric, Brake, Rachael

Volltext

Abstract B28: Identification of drug-response biomarkers for combined mTORC1/2 and MEK1/2 investigational agents using a large-scale cancer cell line screen von Shin, Hyunjin, Blair, Derek, Li, Bin, Hather, Greg, Trepicchio, William L., Ecsedy, Jeffrey, Gangolli, Esha

Volltext

Abstract A41: Automated immunohistochemistry of phosphobiomarkers: Case study of MTOR (MLN0128) and PI3Kα (MLN1117) investigational inhibitors, single agent and in combination, on... von Kreshock, Anna, Iartchouk, Natalia, Cao, Yueying, Szwaya, Jeffrey, Gao, Feng, Simpson, Christopher, Luongo, Evan, Burke, Kristine, Gangolli, Esha, Kuida, Keisuke, Brake, Rachael, Tirrell, Stephen, Shinde, Vaishali

Volltext

Abstract 3738: A rationale for combining the targeted investigational agents TAK-733, a MEK1/2 inhibitor, with alisertib (MLN8237), an Aurora A kinase inhibitor, for cancer therapy von Collins, Sabrina, Blair, Derek, Zarycki, Jodi, Szynal, Carmin, Gangolli, Esha, Vincent, Patrick, Chakravarty, Arijit, Ecsedy, Jeffrey

Volltext

Abstract 3739: TAK-733, an investigational, selective MEK1/2 inhibitor, in combination with alisertib (MLN8237), an investigational, selective Aurora A kinase inhibitor is tolerate... von Fabrey, Robyn, O'Connell, Shawn, Stanton, Andrew, Chakravarty, Arijit, Gangolli, Esha, Ecsedy, Jeffery, Zarycki, Jodi, Vincent, Patrick

Volltext

Reproductive Function in Protein Kinase Inhibitor-Deficient Mice von Belyamani, Mouna, Gangolli, Esha A., Idzerda, Rejean L.

Volltext

MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study von Rasco, Drew Warren, Olszanski, Anthony J., Patnaik, Amita, Espino, Guillermo, Neuwirth, Rachel, Faucette, Stephanie, Bargfrede, Michael, Gangolli, Esha A., Walker, Russell M, Kneissl, Michelle, Bozon, Viviana

Volltext

Abstract 3532: Preclinical-to-clinical translation of optimal schedule for MLN0128, an investigational novel small-molecule selective mTOR1/2 inhibitor, based on exposure-efficacy... von Patel, Mayankbhai, Staunton, Jocelyn, Mettetal, Jerome, Palani, Santhosh, Ecsedy, Jeffrey, Lu, Chuang, Barry, Elly, Westin, Eric, Manfredi, Mark, Shyu, Wej Chyi, Jessen, Katayoun, Gangolli, Esha A., Chakravarty, Arijit

Volltext

Deficient Gene Expression in Protein Kinase Inhibitor α Null Mutant Mice von Gangolli, Esha A., Belyamani, Mouna, Muchinsky, Sara, Narula, Anita, Burton, Kimberly A., McKnight, G. Stanley, Uhler, Michael D., Idzerda, Rejean L.

Volltext

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors von Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey Alan, Pavlick, Anna C., Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha A., Walker, Russell M, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bozon, Viviana

Volltext